Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10-12 October 2007

摘要

Introduction There is mounting evidence describingthe immunosuppressive role of bulky metastatic disease,thus countering the therapeutic effects of tumor vaccine.Therefore, adjuvant immunotherapy may have a betterimpact on clinical outcome. In this phase II clinical trial,we aimed to test the feasibility of using a specific mutantras peptide vaccine as an adjuvant immunotherapy inpancreatic and colorectal cancer patients.Materials and methods Twelve patients with no evidenceof disease (NED), five pancreatic and seven colorectalcancer patients were vaccinated subcutaneously with 13-mer mutant ras peptide, corresponding to their tumor’s rasmutation. Vaccinations were given every 4 weeks, up to atotal of six vaccines.Results No serious acute or delayed systemic side effectswere seen. We detected specific immune responses to therelevant mutant ras peptide by measuring IFN-gammamRNAexpression by quantitative real-time PCR. Five out ofeleven patients showed a positive immune response. Furthermore,the five pancreatic cancer patients have shown amean disease-free survival (DFS) of 35.2+ months and amean overall survival (OS) of 44.4+ months. The sevencolorectal cancer patients have shown a mean disease-freesurvival (DFS) of 27.2+ months and a mean overall survival(OS) of 41.5+ months.